Recent Updates
Recently added Catalysts

MK-3120

Phase 1

Advanced Solid Tumors | Monoclonal antibody | Oncology |Merck & Company, Inc.|Last Updated: May 8, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment270
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06818643A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)PHASE1 RECRUITING 270 — — Mar 25, 2025Mar 25, 2031May 8, 202645 United States, Chile +9
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Who Experience an Adverse Event (AE)
Up to approximately 43 months

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented.

Number of Participants Who Discontinue Study Treatment Due to an AE
Up to approximately 42 months

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Secondary Endpoints
Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as Assessed by the Investigator
Up to approximately 72 months
Duration Of Response (DOR) Per RECIST 1.1 as Assessed by the Investigator
Up to approximately 72 months
Progression-free Survival (PFS) Per RECIST 1.1 as Assessed by the Investigator
Up to approximately 72 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1 Dose level 1EXPERIMENTALParticipants receive MK-3120 at dose level 1 as per the schedule specified in the arm.
Arm 2 Dose level 2EXPERIMENTALParticipants receive MK-3120 at dose level 2 as per the schedule specified in the arm.
Interventions
NameTypeDescription
MK-3120BIOLOGICALIV infusion
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites45

Inclusion Criteria: * Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments * If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART) * If hepatitis B surface antigen (HBs...

Countries:United StatesChileChinaFranceIsraelJapanNetherlandsSouth KoreaSpainTaiwanTurkey (Türkiye)
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06818643primaryCompletionDate: changed
LOWMay 24, 2026NCT06818643studyFirstPostDate: changed